Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial

Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escriva-De-Romani S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, De Boer M, Kim SB, Petrakova K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching P, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ (2021)

Publication Type: Journal article

Publication year: 2021

Journal

DOI: 10.1001/jamaoncol.2020.7932

Abstract

IMPORTANCE ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation.

Authors with CRIS profile

Involved external institutions

University of California San Francisco (UCSF) United States (USA) (US) Seoul National University (SNU) / 서울대학교 Korea, Republic of (KR) Champalimaud Foundation / Fundação Champalimaud Portugal (PT) IOB Institute of Oncology Spain (ES) Università degli studi di Milano Italy (IT) University of Parma / Università degli Studi di Parma Italy (IT) Stanford University United States (USA) (US) Florida Cancer Specialists & Research Institute (FCS) United States (USA) (US) Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron Spain (ES) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Italy (IT) Center François Baclesse France (FR) University of New Mexico (UNM) / Universidad de Nuevo México United States (USA) (US) University of Côte d'Azur / Université Côte d'Azur France (FR) Maastricht University Netherlands (NL) Asan Medical Center / 서울아산병원 Korea, Republic of (KR) Masaryk Memorial Cancer Institute (MMCI) / Masarykův onkologický ústav (MOÚ) Czech Republic (CZ) Tennessee Oncology United States (USA) (US) Lakeridge Health Oshawa Canada (CA) Vejle Sygehus Denmark (DK) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎ Israel (IL) Rabin Medical Center / מרכז רפואי רבין‎‎ Israel (IL) MacroGenics, Inc. United States (USA) (US) Northwestern University United States (USA) (US)

How to cite

APA:

Rugo, H.S., Im, S.-A., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A.,... Gradishar, W.J. (2021). Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.7932

MLA:

Rugo, Hope S., et al. "Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial." JAMA Oncology (2021).

BibTeX: Download